Rofaday 500mcg
| SKU | 2175 |
|---|---|
| Generic For | Daliresp |
| Strength | 500mcg |
| Active Ingredient | Roflumilast |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 0.83 | US$ 25.00 | |||
|
|||||
| 60 Tablet/s | US$ 0.83 | US$ 50.00 | |||
|
|||||
| 90 Tablet/s | US$ 0.83 | US$ 75.00 | |||
|
|||||
Rofaday 500mcg (Roflumilast) – Affordable Daliresp Alternative
Rofaday 500mcg is a prescription treatment for the severe chronic obstructive pulmonary disease in adults. It is extremely effective in reducing inflammation of airways, blockage in lungs and other related conditions. The active ingredient of the medicine is Roflumilast, which controls and prevents symptoms of COPD. These symptoms include wheezing, coughing and shortness of breath. Your doctor may prescribe Rofaday with other bronchodilators such as ipratropium or salmeterol to reduce inflammation to treat COPD. This medication must be used regularly to achieve the maximum results. It does not help with sudden shortness of breath or wheezing.
Read the doctor’s prescription carefully. If you have questions, ask your doctor. Rofaday 500 mcg is available in the form of a tablet. Usually, it is taken once daily with or without food. Roflumilast 500 mcg is enough to reduce the risk of COPD exacerbation in patients with severe COPD. Use this medication to get the most benefit out of it. Make sure you take it at evenly spaced intervals. Do not alter the dosage regimen without first consulting your doctor. The risk of administering this medicine to patients with liver disease should be considered.
Rofaday is not a bronchodilator, therefore it should not be used to gain control over acute bronchospasm. The safety and effectiveness of the drug have not been established in patients less than 18 years of age.
Clinical data revealed an increase in adverse psychiatric reactions in COPD patients who used Rofaday 500 mcg. It is advisable to carefully weigh the risks and benefits of medicine in patients with a history of depression and other mental conditions. One should observe for symptoms such as insomnia, suicidal thoughts, anxiety, depression and other mood changes developed while taking medicine. If you find any often issues mentioned above, consult our doctor, he/she will evaluate the risks and benefits of continuing Rofaday. Weight loss is also a common side effect associated with the use of Roflumilast. Users are instructed to keep a close eye on their weight during the treatment. If unexplained weight loss is the issue, then discontinuation of the drug should be considered. But make sure you consult your doctor before making any decision regarding the medicinal use.
Rofaday 500mcg has been approved for the prevention of chronic obstructive disease. Roflumilast, a phosphodiesterase 4 inhibitor is the active ingredient of the medicine. It effectively targets important goals in the management of COPD such as symptoms relief and reduction of COPD exacerbations. This PDE4 inhibitor has raised hope for more effective COPD treatment. It works by reducing inflammation in the lungs and blockage in the airways, which makes it easier for the patient to breathe.
What is Roflumilast and what condition does it treat?
Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor used to treat severe chronic obstructive pulmonary disease (COPD) in adults. Marketed as Rofaday 500mcg, this anti-inflammatory medication helps reduce flare-ups and exacerbations in patients with chronic bronchitis and a history of frequent symptom worsening. Unlike bronchodilators or inhaled corticosteroids, roflumilast is an oral tablet that works systemically to decrease lung inflammation. It's prescribed alongside regular COPD maintenance inhalers to improve breathing function and reduce hospitalizations related to respiratory decline.
How does Roflumilast work in the body?
Roflumilast works by blocking phosphodiesterase-4, an enzyme that promotes inflammation in the lungs. By inhibiting PDE4, Rofaday 500mcg reduces inflammatory cell activity inside the airways, helping to prevent the tissue damage and mucus overproduction common in severe COPD. This mechanism differs from bronchodilators that open airways or steroids that broadly suppress immune responses. As an oral anti-inflammatory COPD medication, roflumilast decreases the frequency of exacerbations by calming chronic bronchial inflammation at a cellular level, making it easier for patients to maintain stable lung function over time.
How long does Rofaday 500mcg take to work?
Rofaday 500mcg typically begins showing measurable effects within four to eight weeks of consistent daily use. While the active ingredient roflumilast starts inhibiting inflammation soon after absorption, noticeable improvements in COPD exacerbation frequency and breathing function develop gradually. Most patients experience the full therapeutic benefit after approximately three months of continuous treatment. This PDE4 inhibitor is not a rescue medication for sudden breathing difficulty—it's a preventative COPD therapy designed to reduce flare-ups over time. Patience and adherence to your prescribed regimen are essential for optimal respiratory outcomes with this anti-inflammatory tablet.
When and how should I take Rofaday 500mcg?
Take Rofaday 500mcg once daily at the same time each day, with or without food. Swallow the tablet whole with water—do not crush, chew, or split it. Many patients find taking this COPD medication with breakfast helps minimize gastrointestinal side effects like nausea or diarrhea. Roflumilast is a long-term preventative treatment, not a quick-relief inhaler, so consistent daily dosing is crucial for reducing exacerbations. If you miss a dose, take it as soon as you remember unless it's nearly time for your next scheduled tablet. Always follow your healthcare provider's specific instructions regarding timing and dietary considerations.
Is Rofaday 500mcg safe for long-term use?
Rofaday 500mcg is specifically designed for long-term management of severe COPD and has been studied extensively in multi-year clinical trials. The roflumilast safety profile shows that most patients tolerate this PDE4 inhibitor well over extended periods when used as prescribed. Common side effects like weight loss, diarrhea, and nausea often improve after the first few weeks of treatment. However, this anti-inflammatory medication requires ongoing monitoring for mood changes, significant weight reduction, or signs of depression. Long-term use is generally considered safe for appropriate candidates with chronic bronchitis and frequent exacerbations when benefits outweigh individual risk factors.
Can I take Rofaday 500mcg with other medicines?
Rofaday 500mcg can generally be taken alongside most COPD medications including bronchodilators, inhaled corticosteroids, and combination inhalers. However, roflumilast may interact with certain drugs that affect liver enzymes, particularly strong CYP3A4 or CYP1A2 inducers and inhibitors. Medications like rifampicin, phenobarbital, carbamazepine, and some antifungals can alter roflumilast blood levels and effectiveness. This PDE4 inhibitor doesn't typically interfere with common heart medications, diabetes treatments, or blood pressure drugs. Always provide your healthcare provider with a complete list of prescription medications, over-the-counter products, and supplements to ensure safe combination therapy for your respiratory condition.
How does Rofaday 500mcg compare to similar medicines in its class?
Rofaday 500mcg containing roflumilast is currently the only PDE4 inhibitor widely available as an oral tablet for severe COPD management. Unlike inhaled anti-inflammatory medications such as corticosteroids or long-acting bronchodilators, this systemic oral therapy targets inflammatory pathways throughout the respiratory system. Compared to combination inhalers, roflumilast specifically reduces exacerbation frequency rather than providing immediate symptom relief or airway opening. Some patients prefer this once-daily tablet format over multiple daily inhalations. While newer phosphodiesterase inhibitors exist for other conditions, roflumilast remains the established oral anti-inflammatory choice for chronic bronchitis patients with repeated COPD flare-ups.
Is the generic Roflumilast as effective as branded versions?
Generic roflumilast is therapeutically equivalent to branded versions like Rofaday 500mcg and must meet identical standards for purity, strength, and quality. Regulatory agencies in the USA, UK, Canada, and Australia require generic COPD medications to demonstrate bioequivalence—meaning the active ingredient is absorbed at the same rate and extent as the original formulation. The same PDE4 inhibitor molecule works identically regardless of manufacturer, providing the same anti-inflammatory benefits for chronic bronchitis and exacerbation reduction. Many patients and healthcare systems choose generic roflumilast for cost savings without compromising clinical effectiveness in managing severe respiratory disease.
Why do patients choose PremiumRxDrugs for Rofaday 500mcg?
Patients choose PremiumRxDrugs for Rofaday 500 mcg because of its combination of competitive pricing, pharmaceutical authenticity, and customer-focused service. As a licensed international pharmacy with more than 10 years of experience, PremiumRxDrugs supplies manufacturer-sourced roflumilast at prices that are often significantly lower than those at local pharmacies across the USA, UK, Canada, and Australia. The platform simplifies prescription management and offers convenient reordering for long-term COPD treatment. Discreet worldwide shipping with free delivery options ensures privacy and affordability. Patients value the reliability of receiving genuine anti-inflammatory respiratory medications without compromising quality, combined with responsive customer support for ongoing medication needs.
What are the common side effects of Roflumilast?
Common side effects of roflumilast include diarrhea, nausea, weight loss, headache, back pain, and decreased appetite. Gastrointestinal symptoms like stomach discomfort or indigestion affect many patients initially but often improve after several weeks of continued use. Some people experience insomnia, dizziness, or mild tremor while taking this PDE4 inhibitor. Unintentional weight reduction occurs in approximately ten percent of patients using this anti-inflammatory COPD medication. Less common but important effects include mood changes, anxiety, or depressive symptoms. Most adverse reactions are mild to moderate and manageable, though you should report persistent or worsening symptoms to ensure safe continuation of therapy.
Who should avoid taking Roflumilast?
Roflumilast should be avoided by individuals with moderate to severe liver impairment, as the medication is metabolized hepatically and can accumulate to unsafe levels. People with a history of depression, suicidal thoughts, or severe psychiatric disorders should not use this PDE4 inhibitor due to potential mood-related adverse effects. This anti-inflammatory COPD therapy is not recommended for pregnant or breastfeeding women, as safety data remains limited. Patients with unexplained or significant weight loss should discuss alternative treatments. Roflumilast is not appropriate for mild COPD or as a rescue medication during acute breathing emergencies. Always disclose your complete medical history before starting this respiratory treatment.
Login
Sign Up
Login
Sign Up